The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Inhibition of LFA‐1/ICAM‐1 and VLA‐4/VCAM‐1 as a therapeutic approach to inflammation and autoimmune diseases
Abstract
This review focuses on providing insights into the structural basis and clinical relevance of LFA‐1 and VLA‐4 inhibition by peptides and small molecules as adhesion‐based therapeutic strategies for inflammation and autoimmune diseases. Interactions of cell adhesion molecules (CAM) play central roles in mediating immune and inflammatory responses. Leukocyte function‐associated antigen (LFA‐1, α L β 2, and CD11a/CD18) and very late antigen (VLA‐4, α 4 β 1, and CD49d/CD29) are members of integrin‐type CAM that are predominantly involved in leukocyte trafficking and extravasation. LFA‐1 is exclusively expressed on leukocytes and interacts with its ligands ICAM‐1, ‐2, and ‐3 to promote a variety of homotypic and heterotypic cell adhesion events required for normal and pathologic functions of the immune systems. VLA‐4 is expressed mainly on lymphocyte, monocytes, and eosinophils, but is not found on neutrophils. VLA‐4 interacts with its ligands VCAM‐1 and fibronectin (FN) CS1 during chronic inflammatory diseases, such as rheumatoid arthritis, asthma, psoriasis, transplant‐rejection, and allergy. Block‐ade of LFA‐1 and VLA‐4 interactions with their ligands is a potential target for immunosuppression. LFA‐1 and VLA‐4 antagonists (antibodies, peptides, and small molecules) are being developed for controlling inflammation and autoimmune diseases. The therapeutic intervention of mostly mAb‐based has been extensively studied. However, due to the challenging relative efficacy/safety ratio of mAb‐based therapy application, especially in terms of systemic administration and immunogenic potential, strategic alternatives in the forms of peptide, peptide mimetic inhibitors, and small molecule non‐peptide antagonists are being sought. Linear and cyclic peptides derived from the sequences of LFA‐1, ICAM‐1, ICAM‐2, VCAM‐1, and FN C1 have been shown to have inhibitory effects in vitro and in vivo. Finally, understanding the mechanism of LFA‐1 and VLA‐4 binding to their ligands has become a fundamental basis in developing therapeutic agents for inflammation and autoimmune diseases. © 2002 John Wiley& Sons, Inc. Med Res Rev, 22, No. 2, 146–167, 2002; DOI 10.1002/med.10001
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
Springer, T. A. (1994) · Cell · doi:10.1016/0092-8674(94)90337-9 · Cited by 6,929
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., & Dustin, M. L. (1999) · Science · doi:10.1126/science.285.5425.221 · Cited by 3,102
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Inhibition of NF-κB by Sodium Salicylate and Aspirin
Kopp, E., & Ghosh, S. (1994) · Science · doi:10.1126/science.8052854 · Cited by 1,753
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Organ targeting In vivo using phage display peptide libraries
Pasqualini, R., & Ruoslahti, E. (1996) · Nature · doi:10.1038/380364a0 · Cited by 1,221
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of asthma
Wegner, C. D., Gundel, R. H., Reilly, P., Haynes, N., Letts, L. G., & Rothlein, R. (1990) · Science · doi:10.1126/science.1967851 · Cited by 898
Staunton, D. E., Dustin, M. L., Erickson, H. P., & Springer, T. A. (1990) · Cell · doi:10.1016/0092-8674(90)90805-o · Cited by 697
Research works printed but not linked: 51
- Gürsoy RN, 1997, Inhibition of ICAM‐1/LFA‐1 interactions for inducing immunotolerance, Curr Top Pept Prot Res, 2, 53
- 10.1126/science.285.5425.207 · doi:10.1126/science.285.5425.207
- Yusuf‐Makagiansar H, 2000, Modulation of adhesion molecules in lymphocyte activation and cell–cell interaction, Curr Top Biochem Res, 2, 33
- Giddings JC, 1999, Intercellular adhesion in vascular biology, thrombosis and cancer, Br J Biomed Sci, 56, 66
- 10.1111/j.1445-2197.1996.tb00752.x · doi:10.1111/j.1445-2197.1996.tb00752.x
- 10.3109/15419060009109020 · doi:10.3109/15419060009109020
- 10.1159/000179238 · doi:10.1159/000179238
- 10.1016/S0168-1702(99)00038-6 · doi:10.1016/s0168-1702(99)00038-6
- 10.1074/jbc.271.39.23920 · doi:10.1074/jbc.271.39.23920
- 10.1053/beha.1999.0050 · doi:10.1053/beha.1999.0050
- Nakajima S, 1995, A hierarchy for integrin expression and adhesiveness among T cell subsets that is linked to TCR gene usage and emphasizes Vd1 + gd T cell adherence and tissue retention, J Immunol, 155, 1117, 10.4049/jimmunol.155.3.1117 · doi:10.4049/jimmunol.155.3.1117
- 10.1002/eji.1830270106 · doi:10.1002/eji.1830270106
- 10.1111/j.1365-2249.1993.tb03413.x · doi:10.1111/j.1365-2249.1993.tb03413.x
- Clark CL, 1990, Lymphocyte infiltration patterns in rat small‐bowel transplants, Transplant Proc, 22, 2460
- 10.1006/cimm.1996.1050 · doi:10.1006/cimm.1996.1050
- 10.1016/S0165-2478(99)00133-9 · doi:10.1016/s0165-2478(99)00133-9
- 10.1016/S0198-8859(00)00101-4 · doi:10.1016/s0198-8859(00)00101-4
- 10.1038/ki.1997.202 · doi:10.1038/ki.1997.202
- 10.1136/jcp.49.3.238 · doi:10.1136/jcp.49.3.238
- 10.1016/S0002-9440(10)65296-0 · doi:10.1016/s0002-9440(10)65296-0
- 10.1073/pnas.93.10.4821 · doi:10.1073/pnas.93.10.4821
- 10.1097/00007890-199506150-00013 · doi:10.1097/00007890-199506150-00013
- Isobe M, 1994, Immunosuppression to cardiac allografts and soluble antigens by anti‐vascular cellular adhesion molecule‐1 and anti‐very late antigen‐4 monoclonal antibodies, J Immunol, 153, 5810, 10.4049/jimmunol.153.12.5810 · doi:10.4049/jimmunol.153.12.5810
- 10.1136/gut.47.1.97 · doi:10.1136/gut.47.1.97
- Molina A, 1994, Prevention of mercuric chloride‐induced nephritis in the brown Norway rat by treatment with antibodies against the α4 integrin, J Immunol, 153, 2313, 10.4049/jimmunol.153.5.2313 · doi:10.4049/jimmunol.153.5.2313
- 10.1074/jbc.M008967200 · doi:10.1074/jbc.m008967200
- Labadia ME, 1998, Molecular regulation of the interaction between leukocyte function‐associated antigen‐1 and soluble ICAM‐1 by divalent metal cations, J Immunol, 161, 836, 10.4049/jimmunol.161.2.836 · doi:10.4049/jimmunol.161.2.836
- 10.1084/jem.183.3.1247 · doi:10.1084/jem.183.3.1247
- 10.1016/S0167-5699(99)01467-X · doi:10.1016/s0167-5699(99)01467-x
- 10.1002/jlb.66.1.67 · doi:10.1002/jlb.66.1.67
- 10.1073/pnas.96.6.3017 · doi:10.1073/pnas.96.6.3017
- 10.1038/387312a0 · doi:10.1038/387312a0
- 10.1074/jbc.270.11.5979 · doi:10.1074/jbc.270.11.5979
- 10.1164/ajrccm.156.3.9609039 · doi:10.1164/ajrccm.156.3.9609039
- Vanderslice P, 1997, A cyclic hexapeptide is a potent antagonist of α4 integrins, J Immunol, 158, 1710, 10.4049/jimmunol.158.4.1710 · doi:10.4049/jimmunol.158.4.1710
- 10.1016/S0021-9258(18)54139-9 · doi:10.1016/s0021-9258(18)54139-9
- 10.1074/jbc.270.31.18401 · doi:10.1074/jbc.270.31.18401
- 10.1042/bj3270727 · doi:10.1042/bj3270727
- 10.1038/sj.bjp.0702511 · doi:10.1038/sj.bjp.0702511
- 10.1016/S0960-894X(00)00088-3 · doi:10.1016/s0960-894x(00)00088-3
- 10.1016/S0960-894X(00)00089-5 · doi:10.1016/s0960-894x(00)00089-5
- 10.1111/j.1399-3011.1999.tb01613.x · doi:10.1111/j.1399-3011.1999.tb01613.x
- 10.1080/07391102.1999.10508375 · doi:10.1080/07391102.1999.10508375
- 10.1016/S0196-9781(00)00255-2 · doi:10.1016/s0196-9781(00)00255-2
- 10.1089/aid.1993.9.733 · doi:10.1089/aid.1993.9.733
- 10.1016/0014-5793(91)80475-I · doi:10.1016/0014-5793(91)80475-i
- 10.1002/1099-1387(200008)6:8<398::AID-PSC270>3.0.CO;2-1 · doi:10.1002/1099-1387(200008)6:8<398::aid-psc270>3.0.co;2-1
- 10.1097/00007890-199803150-00017 · doi:10.1097/00007890-199803150-00017
- Gerli R, 1998, Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells, Blood, 92, 2389, 10.1182/blood.V92.7.2389 · doi:10.1182/blood.v92.7.2389
- 10.1002/1529-0131(199809)41:9<1677::AID-ART20>3.0.CO;2-4 · doi:10.1002/1529-0131(199809)41:9<1677::aid-art20>3.0.co;2-4
- 10.1006/excr.1994.1139 · doi:10.1006/excr.1994.1139
Cited by
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Nanotechnology-based drug delivery systems
Suri, S. S., Fenniri, H., & Singh, B. (2007) · Journal of Occupational Medicine and Toxicology · doi:10.1186/1745-6673-2-16 · Cited by 755
Salomonsson, S., Jonsson, M. V., Skarstein, K., Brokstad, K. A., Hjelmström, P., Wahren‐Herlenius, M., & Jonsson, R. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11311 · Cited by 472
Getting Leukocytes to the Site of Inflammation
Muller, W. A. (2013) · Veterinary Pathology · doi:10.1177/0300985812469883 · Cited by 400
Ulbrich, H., Eriksson, E. E., & Lindbom, L. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.10.004 · Cited by 354
Metadata
- Authors
- Yusuf‐Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2002-02-08
- Volume
- 22
- Issue
- 2
- Pages
- 146-167
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2050681882
- Cited by
- 408
- References
- 114
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of LFA‐1/ICAM‐1 and VLA‐4/VCAM‐1 as a therapeutic approach to inflammation and autoimmune diseases. https://app.cochat.ai/papers/10.1002/med.10001
- The paper
- Yusuf‐Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J. (2002). Inhibition of LFA‐1/ICAM‐1 and VLA‐4/VCAM‐1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.10001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.